Proteon raises $12M in first round

Waltham, MA-based Proteon Therapeutics has added an additional $12 million to its first round of financing, bringing the total to $31 million. Back in March 2006, the company raised $19 million. TVM Capital, Skyline Ventures, Prism VentureWorks and Intersouth Partners participated in the round. Proteon plans to advance its first product candidate, PRT-201, into human clinical studies in both hemodialysis vascular access and peripheral arterial disease. Proteon also added Mark J. Fitzpatrick as its Vice President and CFO.

- see this release

Suggested Articles

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.